# Metacrine Inc. (MTCR)

Source: https://www.quantisnow.com/company/MTCR
Generated: 2026-11-12T13:34:58.203Z

- Ticker: MTCR
- Exchange: NASDAQ
- Sector: Health Care
- Industry:  Medicinal Chemicals and Botanical Products 
- IPO year: 2020
- Website: metacrine.com

## About

Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with liver and gastrointestinal diseases. It is developing MET409 that has completed Phase 1b proof-of-concept clinical trial for the treatment of patients with non-alcoholic steatohepatitis (NASH); and is in Phase 2a clinical trial in combination with empagliflozin for the treatment of patients with type 2 diabetes mellitus and NASH. The company also develops MET642, which is in Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis patients. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

## Latest MTCR news and filings

- 2023-03-24 21:29 UTC [SEC Form 15-12G filed by Metacrine Inc.](https://www.quantisnow.com/insight/sec-form-15-12g-filed-by-metacrine-inc-4248082)
- 2023-03-24 21:28 UTC [SEC Form 8-K] [Metacrine Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Leadership Update, Submission of Matters to a Vote of Security Holders](https://www.quantisnow.com/insight/metacrine-inc-filed-sec-form-8-k-material-modification-to-rights-4248057)
- 2023-03-24 16:35 UTC [SEC Form 4] [SEC Form 4 filed by Klassen Preston](https://www.quantisnow.com/insight/sec-form-4-filed-by-klassen-preston-4246150)
- 2023-03-23 20:34 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Metacrine Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-metacrine-inc-4242659)
- 2023-03-23 20:32 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Metacrine Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-metacrine-inc-4242624)
- 2023-03-23 20:31 UTC [SEC Form 8-K] [Metacrine Inc. filed SEC Form 8-K: Leadership Update](https://www.quantisnow.com/insight/metacrine-inc-filed-sec-form-8-k-leadership-update-4242578)
- 2023-03-15 21:20 UTC [SEC Form 8-K] [Metacrine Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets](https://www.quantisnow.com/insight/metacrine-inc-filed-sec-form-8-k-entry-into-a-material-4208258)
- 2023-03-08 05:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Metacrine Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-metacrine-inc-4170903)
- 2023-03-03 15:44 UTC [SEC Form 25-NSE filed by Metacrine Inc.](https://www.quantisnow.com/insight/sec-form-25-nse-filed-by-metacrine-inc-4159076)
- 2023-02-14 21:00 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed by Metacrine Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-by-metacrine-inc-amendment-4062554)
- 2023-02-13 13:30 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by Metacrine Inc.](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-metacrine-inc-4045651)
- 2023-02-09 21:06 UTC [SEC Form 8-K] [Metacrine Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Events That Accelerate or Increase a Direct Financial Obligation](https://www.quantisnow.com/insight/metacrine-inc-filed-sec-form-8-k-termination-of-a-material-4034007)
- 2023-02-08 20:43 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed by Metacrine Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-by-metacrine-inc-amendment-4024408)
- 2023-02-03 22:08 UTC [SEC Form 8-K] [Metacrine Inc. filed SEC Form 8-K: Leadership Update](https://www.quantisnow.com/insight/metacrine-inc-filed-sec-form-8-k-leadership-update-4004092)
- 2023-02-01 21:30 UTC [Market Insight] [12 Health Care Stocks Moving In Wednesday's After-Market Session](https://www.quantisnow.com/insight/12-health-care-stocks-moving-in-wednesdays-after-market-session-3989637)
- 2023-02-01 21:16 UTC [SEC Form 8-K] [Metacrine Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing](https://www.quantisnow.com/insight/metacrine-inc-filed-sec-form-8-k-notice-of-delisting-or-3989347)
- 2023-01-27 21:44 UTC [SEC Form 4] [SEC Form 4: York Michael sold $44,331 worth of shares (107,054 units at $0.41), decreasing direct ownership by 51% to 103,499 units (tax withholding)](https://www.quantisnow.com/insight/sec-form-4-york-michael-sold-44331-worth-of-shares-3967868)
- 2023-01-27 21:42 UTC [SEC Form 4] [SEC Form 4: Klassen Preston sold $157,266 worth of shares (380,605 units at $0.41), decreasing direct ownership by 41% to 541,905 units (tax withholding)](https://www.quantisnow.com/insight/sec-form-4-klassen-preston-sold-157266-worth-of-shares-3967858)
- 2023-01-24 22:19 UTC [Market Insight] [Metacrine Says President, CEO, Secretary, Principal Executive Officer Preston Klassen Was Terminated From Positions, Effective Feb. 1](https://www.quantisnow.com/insight/metacrine-says-president-ceo-secretary-principal-executive-officer-preston-klassen-3949025)
- 2023-01-24 22:17 UTC [SEC Form PRE 14A] [SEC Form PRE 14A filed by Metacrine Inc.](https://www.quantisnow.com/insight/sec-form-pre-14a-filed-by-metacrine-inc-3949010)
- 2023-01-24 22:13 UTC [SEC Form 8-K] [Metacrine Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/metacrine-inc-filed-sec-form-8-k-leadership-update-other-events-3948982)
- 2022-12-27 09:12 UTC [Market Insight] [Metacrine, Equillium And 3 Stocks To Watch Heading Into Tuesday](https://www.quantisnow.com/insight/metacrine-equillium-and-3-stocks-to-watch-heading-into-tuesday-3844372)
- 2022-12-23 21:30 UTC [Market Chatter] [Metacrine Shares Resume Trade Following Circuit Breaker Halt, Stock Now Up 14%](https://www.quantisnow.com/insight/metacrine-shares-resume-trade-following-circuit-breaker-halt-stock-now-3842785)
- 2022-12-23 21:15 UTC [SEC Form 8-K] [Metacrine Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/metacrine-inc-filed-sec-form-8-k-termination-of-a-material-3842636)
- 2022-12-23 21:02 UTC [Market Chatter] [Metacrine and Equillium Mutually Agree to Terminate Definitive Merger Agreement](https://www.quantisnow.com/insight/metacrine-and-equillium-mutually-agree-to-terminate-definitive-merger-agreement-3842441)
- 2022-12-23 21:01 UTC [Market Chatter] [Metacrine Shares Halted, News Pending](https://www.quantisnow.com/insight/metacrine-shares-halted-news-pending-3842438)
- 2022-12-23 21:01 UTC [Metacrine and Equillium Mutually Agree to Terminate Definitive Merger Agreement](https://www.quantisnow.com/insight/metacrine-and-equillium-mutually-agree-to-terminate-definitive-merger-agreement-3842420)
- 2022-12-21 22:49 UTC [SEC Form 4] [SEC Form 4: Leonard Braden Michael bought $107,594 worth of shares (271,605 units at $0.40)](https://www.quantisnow.com/insight/sec-form-4-leonard-braden-michael-bought-107594-worth-of-3835068)
- 2022-12-20 18:19 UTC [Market Insight] [Why IceCure Medical Shares Are Trading Higher By 296%? Here Are 64 Stocks Moving In Tuesday's Mid-Day Session](https://www.quantisnow.com/insight/why-icecure-medical-shares-are-trading-higher-by-296-here-3828135)
- 2022-12-20 11:13 UTC [Market Insight] [Why Entrada Therapeutics Shares Are Trading Lower By 32%; Here Are 31 Stocks Moving Premarket](https://www.quantisnow.com/insight/why-entrada-therapeutics-shares-are-trading-lower-by-32-here-3825435)
- 2022-12-19 21:31 UTC [Market Insight] [12 Health Care Stocks Moving In Monday's After-Market Session](https://www.quantisnow.com/insight/12-health-care-stocks-moving-in-mondays-after-market-session-3823737)
- 2022-12-19 21:03 UTC [Market Chatter] [Tang Capital Partners Reports In 13G Filing A 7.1% Stake In Metacrine](https://www.quantisnow.com/insight/tang-capital-partners-reports-in-13g-filing-a-71-stake-3823223)
- 2022-12-19 21:00 UTC [SEC Schedule 13G] [SEC Form SC 13G filed by Metacrine Inc.](https://www.quantisnow.com/insight/sec-form-sc-13g-filed-by-metacrine-inc-3823173)
- 2022-12-15 02:52 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Metacrine Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-metacrine-inc-3808888)
- 2022-12-08 17:08 UTC [SEC Schedule 13D] [SEC Form SC 13D filed by Metacrine Inc.](https://www.quantisnow.com/insight/sec-form-sc-13d-filed-by-metacrine-inc-3784521)
- 2022-12-06 17:17 UTC [Market Insight] [Autoimmune Biotech Scores $26M Payment, Up To $139M To Advance Phase 3 Research](https://www.quantisnow.com/insight/autoimmune-biotech-scores-26m-payment-up-to-139m-to-advance-3773344)
- 2022-11-14 21:38 UTC [Metacrine Reports Third-Quarter 2022 Results](https://www.quantisnow.com/insight/metacrine-reports-third-quarter-2022-results-3683319)
- 2022-11-14 21:22 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Metacrine Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-metacrine-inc-3682762)
- 2022-11-14 21:20 UTC [SEC Form 425] [SEC Form 425 filed by Metacrine Inc.](https://www.quantisnow.com/insight/sec-form-425-filed-by-metacrine-inc-3682485)
- 2022-11-14 21:15 UTC [SEC Form 8-K] [Metacrine Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/metacrine-inc-filed-sec-form-8-k-results-of-operations-and-3682194)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/MTCR
- Earnings history: https://www.quantisnow.com/earnings/MTCR
- Dividend history: https://www.quantisnow.com/dividends/MTCR
- Insider transactions: https://www.quantisnow.com/insiders/MTCR
- Options chain: https://www.quantisnow.com/options/MTCR
- SEC 8-K filings only: https://www.quantisnow.com/company/MTCR/8-k
- RSS and alerts for MTCR: https://www.quantisnow.com/docs/rss-feeds.md